Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Mini Review - Journal of Molecular Oncology Research (2022) Volume 6, Issue 6

Novel oncogenes and tumor silencer qualities in hepatocellular carcinoma.

Wei Qiu*

Department of Surgery and Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA

Corresponding Author:
Wei Qiu
Department of Surgery and Cancer Biology
Loyola University Chicago Stritch School of Medicine
Maywood, IL, USA

Received: 25-May-2022, Manuscript No. AAMOR-22-65884; Editor assigned: 27-May-2022, Pre QC No. AAMOR-22-65884(PQ); Reviewed: 10-June-2022, QC No. AAMOR-22-65884; Revised: 17-June-2022; AAMOR-22-65884(R); Published: 24-June-2022, DOI: 10.35841/aamor-6.6.129

Citation: Qiu W. Novel oncogenes and tumor silencer qualities in hepatocellular carcinoma. J Mol Oncol Res. 2022;6(6):129.

Visit for more related articles at Journal of Molecular Oncology Research


Hepatocellular carcinoma (HCC) could be an exceptionally dangerous malady. HCC start and movement include numerous hereditary occasions, counting the actuation of proto-oncogenes and disturbance of the work of particular tumor silencer qualities. Actuation of oncogenes fortifies cell development and survival, whereas loss-of-function transformations of tumor silencer qualities result in over the top cell development. In this survey, we summarize the modern discoveries that distinguished novel proto-oncogenes and tumor silencers in HCC over the past five a long time. These discoveries may motivate the improvement of novel helpful procedures to move forward the result of HCC patients.


Hepatocellular carcinoma, Oncogene, Tumor suppressor, Activation, Loss-of-function.


Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide.1 There are numerous chance variables for HCC, such as contaminations with hepatitis B infection or hepatitis C infection, persistent liquor utilize, aflatoxin, immune system hepatitis, weight, and diabetes [1]. Current treatments give constrained clinical advantage for these patients.2 distant better;A much better;A higher;A stronger;An improved">An improved understanding of the atomic components of HCC improvement is basic for creating modern viable helpful procedures for treating it. HCC start and movement include different hereditary occasions, such as the actuation of protooncogenes and disturbance of the capacities of particular tumor silencer qualities. Oncoproteins encoded by oncogenes invigorate or improve the division and reasonability of cells.4 In differentiate, tumor silencer qualities can straightforwardly or by implication anticipate cell multiplication or result in cell passing. Tumor protein p53 (P53), phosphatase and tensin homolog (PTEN), axin 1 (AXIN 1), and retinoblastoma transcriptional corepressor 1 (RB1) are well-known tumor silencer qualities in HCC [2].

P53 is changed or quieted in 30–60% of HCC, whereas PTEN is misplaced in over 40% of HCC.5,6 In 2015, Kanda et al.7 summarized the capacities of putative oncogenes and tumor silencers in HCC. Too, in a later uncommon issue of Liver Inquire about, a few determination markers, such as Golgi protein, Glypican-3, Galectin-1 and Galectin-3, Yesassociated protein-1 for HCC were discussed. In any case, these biomarkers don't fundamentally practically contribute to HCC start and movement. This audit gives an upgraded outline of as of late distributed articles from the past five a long time tending to HCC-related oncogenes (30 qualities) and tumor silencer qualities (12 qualities), which practically contribute to HCC start and movement. These qualities are presented since the ponders on capacities of these qualities in HCC have possibly noteworthy impacts on the disclosure, pathogenesis, or treatment of liver cancer. These discoveries may fortify the advancement of novel helpful methodologies for the treatment of HCC [3].

ABL proto-oncogene , non-receptor tyrosine kinase (ABL1) was to begin with found as an oncogene in human leukemia more than 30 a long time prior. ABL inhibitors have been exceptionally effectively utilized for the treatment of breakpoint cluster locale (BCR)-ABL1-positive leukemia. As of late, actuation of ABL1 has been recognized in numerous strong tumors. In any case, for a long time, the part of ABL1 within the advancement of HCC was not known. Unthinkingly, we found that restraint of ABL1 diminishes the expression of c-MYC and indent receptor 1 (NOTCH1) and stifles HCC cell growth. We moreover found a solid relationship between ABL1, c-MYC, and NOTCH1 in human HCC specimens. Altogether, ABL1 inhibitors stifled HCC development in xenograft and oncogene-driven HCC models. Generally, these comes about propose that ABL1 plays a significant part in advancing HCC advancement.

Annexins are Ca2+-regulated phospholipid-binding proteins that play crucial parts in cell multiplication, exocytosis, and cell death. Twelve annexin proteins (A1–12) have been distinguished in humans. A few Annexin proteins have been appeared to operate as putative oncoproteins in HCC advancement. Annexin A3 (ANXA3) expression is considerably lifted in HCC tissues in comparison to adjoining typical tissues. In differentiate, the knockdown of ANXA3 represses these forms. Its barricade with an anti-ANXA3 counter acting agent comes about in a noteworthy lessening in tumor growth. Also, overexpression of ANXA3 in HCC cells improves resistance to treatment with sorafenib and regorafenib. Robotically, upregulated ANXA3 stifles protein kinase C delta (PKCδ)/p38-associated apoptosis and actuates autophagy in sorafenib-resistant HCC cells. Altogether, anti- ANXA3 monoclonal counter acting agent treatment improves the proficiency of sorafenib/regorafenib in stifling HCC tumor development in vivo. In differentiate, the knockdown of ANXA3 represses ANXA4, another part of the Annexin A family, is another putative proto-oncogene in HCC. Serum ANXA4 levels are significantly more prominent in HCC patients than patients with cirrhosis of the liver and solid controls. Overexpression of ANXA4 advances HCC cell expansion, and the downregulated expression of ANXA4 represses HCC cell development and tumorigenesis [4].

So also, tall expression of ANXA2 advances the movement of HCC and predicts destitute prognosis.23 Robotically, ANXA2 upgrades HCC movement by means of the remodeling of cell motility-associated structures and interaction with engulfment and cell motility protein. FAK, a non-receptor tyrosine kinase, advances tumor development and movement by kinase-dependent and -autonomous pathways. In spite of the fact that FAK capacities in other sorts of cancer have been expectation considered, and it was known that FAK is overexpressed in HCC examples. FAK's exact part in HCC remained tricky within the past. Our lab created hepatocytespecific FAK-knockout mice. We found that misfortune of FAK significantly smothers cellular-mesenchymal epithelial move figure (c-MET)/β-catenin-induced tumor development and draws out animals' survival in this demonstrate. Robotically, we found that c-MET enacts FAK, which is basic for the actuation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) in HCC cells. β-catenin does not specifically enact FAK; instep, it improves the actuation of FAK by c-MET. Encourage, we illustrated that FAK advances c-MET/β-catenin-induced HCC through its kinase activity.30 Reliably, the FAK kinase inhibitor PF-562271 stifles the movement of HCC in mouse models. FAK can moreover direct enhancer of zeste homolog 2 (EZH2), which tweaks translation of p53, E2F2/3, and NOTHC2 to advance HCC cell development. as of late found that FAK overexpression alone is deficiently to initiate HCC; instep, FAK coordinates with β-catenin to initiate HCC. Reliable with this, one-third of human HCC tests with FAK enhancement are coincidental with β-catenin mutations. Robotically, expanded expression of FAK increments androgen receptor (AR) expression by upgrading the official of β-catenin to AR's promoter. Critically, restraint of AR smothers FAK/β-catenin-induced HCC development [5].


  1. Wang Y, Wan YY. Golgi protein 73, hepatocellular carcinoma and other types of cancers. Liver Res. 2020; 4:161-67.
  2. Indexed at, Google Scholar, Cross Ref

  3. Shih TC, Wang L, Wang HC, et al. Glypican-3: a molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Res. 2020; 4:168-72.
  4. Indexed at, Google Scholar, Cross Ref

  5. Greuber EK, Smith-Pearson P, Wang J, et al. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13:559-71.
  6. Indexed at, Google Scholar, Cross Ref

  7. Wang F, Hou W, Chitsike L, et al. ABL1, overexpressed in hepatocellular carcinomas, regulates expression of NOTCH1 and promotes development of liver tumors in mice. Gastroenterol. 2020; 159:289-05.
  8. Indexed at, Google Scholar, Cross Ref

  9. Tong M, Che N, Zhou L, et al. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol. 2018;69:826-39.
  10. Indexed at, Google Scholar, Cross Ref

Get the App